Coexisting atrial fibrillation and diabetes mellitus represent a high-risk population requiring aggressive risk factor identification and treatment optimization to minimize modifiable risk factors.
Patients with comorbid atrial fibrillation and diabetes mellitus require individualized, multifactorial risk assessment and aggressive treatment optimization to minimize cardiovascular risk.
INTRODUCTION: Atrial fibrillation (AF) and diabetes mellitus (DM) are common worldwide and their incidence is increasing, representing a significant public health and economic burden as well as an increase in individual increased morbidity and mortality risk profiles. Both conditions are closely related, as patients with DM are at increased risk of incident AF, and AF patients with DM are at higher risk of cardiovascular events compared to non-AF patients. Areas covered: This review article aims to provide an overview of the current evidence linking DM and AF, as well as the impact of obesity, weight loss and stroke on these coexisting conditions. Second, the effects of new oral anti hyperglycaemic medications on cardiovascular risk will be considered. Expert opinion: In conclusion, coexisting AF and DM represent a high risk population of patients requiring aggressive risk factor identification and treatment optimisation. The multifactorial interplay between these conditions requires individual assessment of patient risk profiles with the aim of minimising the impact of each modifiable risk factor.
Moss et al. (Sat,) conducted a review in Atrial fibrillation and diabetes mellitus. Risk factor identification and treatment optimization was evaluated. Coexisting atrial fibrillation and diabetes mellitus represent a high-risk population requiring aggressive risk factor identification and treatment optimization to minimize modifiable risk factors.